相似文献
1
What, if Any, Role Is There for BRAF-Targeted Therapy in -Mutant Melanoma?
J Clin Oncol. 2022 Dec 20;40(36):4161-4165. doi: 10.1200/JCO.22.01066. Epub 2022 Jul 21.
2
Sequencing of Targeted Treatment and Immunotherapy in Advanced -Mutant Melanoma.
J Clin Oncol. 2023 Apr 20;41(12):2295-2296. doi: 10.1200/JCO.22.02250. Epub 2023 Feb 15.
3
Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Hematol Oncol Clin North Am. 2014 Jun;28(3):523-36. doi: 10.1016/j.hoc.2014.03.001.
4
Targeted therapies for cutaneous melanoma.
Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3.
5
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30.
6
Targeted therapy for melanoma: rational combinatorial approaches.
Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18.
7
Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
J Invest Dermatol. 2014 May;134(5):1468-1470. doi: 10.1038/jid.2013.378. Epub 2013 Sep 11.
8
Therapeutic targets in melanoma: map kinase pathway.
Curr Oncol Rep. 2006 Sep;8(5):400-5. doi: 10.1007/s11912-006-0065-x.
10
Targeted Therapy in Advanced Melanoma With Rare Mutations.
J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3.
引用本文的文献
1
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring mutations.
Transl Lung Cancer Res. 2023 Feb 28;12(2):219-229. doi: 10.21037/tlcr-22-613. Epub 2023 Feb 25.
本文引用的文献
1
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
Cancer. 2023 Jun 15;129(12):1904-1918. doi: 10.1002/cncr.34730. Epub 2023 Apr 11.
2
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With V600-Mutant Melanoma.
J Clin Oncol. 2022 Dec 20;40(36):4178-4188. doi: 10.1200/JCO.21.02659. Epub 2022 Jul 21.
3
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Eur J Cancer. 2022 May;167:32-41. doi: 10.1016/j.ejca.2022.02.023. Epub 2022 Mar 30.
4
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.
J Clin Oncol. 2022 May 1;40(13):1428-1438. doi: 10.1200/JCO.21.01601. Epub 2022 Jan 14.
5
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
Clin Cancer Res. 2022 Mar 15;28(6):1098-1106. doi: 10.1158/1078-0432.CCR-21-3382.
6
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
7
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.
Clin Cancer Res. 2021 Oct 1;27(19):5225-5235. doi: 10.1158/1078-0432.CCR-21-0809.
8
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12.
9
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Br J Cancer. 2021 Feb;124(3):574-580. doi: 10.1038/s41416-020-01121-y. Epub 2020 Oct 22.
10
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol. 2020 Nov;21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0. Epub 2020 Sep 19.
Zotero 插件